查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1769646

2025年全球液态切片市场报告

Lung Cancer Liquid Biopsy Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 175 Pages | 商品交期: 2-10个工作天内

价格
简介目录

预计未来几年肺癌液态切片市场规模将快速成长。到 2029 年，该市场规模将成长至 20.8 亿美元，复合年增长率为 16.8%。预测期内的增长归因于肺癌发病率上升、对非侵入性诊断方法的需求不断增长、个人化医疗的普及、早期癌症检测意识的增强以及易患癌症的老年人口的增长。预计这段时期的主要趋势包括循环肿瘤 DNA (ctDNA) 分析技术的进步、基于外泌体的液态切片技术的进步、用于分离循环性肿瘤细胞的微流体的创新、用于生物标誌物解读的人工智慧和机器学习的整合，以及实现多重生物标记分析的技术突破。

预计未来几年肺癌发生率的上升将推动肺癌液态切片市场的成长。肺癌是一种以肺部异常细胞不受控制地增殖为特征的病理，通常与吸烟和环境暴露有关。患者数量的增加主要归因于持续使用烟草，烟草使肺部暴露于致癌物质引发细胞异常增殖。肺癌液态切片可以透过简单的血液样本检测癌症相关的基因突变和肿瘤DNA，从而促进早期诊断、个人化治疗选择以及持续监测病情进展和疗效。例如，美国癌症协会在2023年报告称，截至2022年1月1日，美国有654,620人有肺癌病史，其中许多人患有转移性疾病。这些患者中约80%年龄在65岁或以上，55%是在过去五年内确诊的，这意味着患者存活率较低。因此，肺癌发生率的上升显着促进了肺癌液态切片市场的扩张。

肺癌液态切片市场的主要企业正在优先考虑技术进步，例如开发基于血液的肺癌筛检测试市场，目的是早期发现、提高诊断准确性并提供对肿瘤进展和治疗反应的非侵入性即时监测。这种基于血液的筛检测试分析血液中的生物标记以早期发现肺癌，为传统方法提供了一种侵入性较小的替代方法。例如，2023 年 10 月，美国生物技术公司 DELFI Diagnostics Inc. 推出了 FirstLook Lung，这是一种基于血液的液态切片测试，用于早期发现肺癌。此测试利用片段组学以高灵敏度辨识早期肺癌，阴性预测值为 99.8%。该测试旨在成为高风险族群的一种便捷的早期筛检工具，旨在提高早期发现率，增加筛检参与度，并帮助将诊断成像资源优先提供给最有可能受益的人群。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场：宏观经济情景，包括利率、通膨、地缘政治、贸易战和关税，以及新冠疫情和復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球肺癌液态切片：PESTEL分析（政治、社会、技术、环境、法律因素、驱动因素和限制因素）
  • 最终用途产业分析
  • 全球液态切片市场：成长率分析
  • 全球液态切片市场表现：规模与成长，2019-2024
  • 全球液态切片市场预测：2024-2029年及2034年规模与成长
  • 全球肺癌液态切片：总目标市场（TAM）

第六章市场区隔

  • 全球肺癌液态切片市场：依产品、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 装置
  • 耗材套件和试剂
  • 软体和服务
  • 全球液态切片市场（依技术、绩效及预测），2019-2024 年、2024-2029 年、2034 年
  • 多基因平行分析（NGS）
  • 单基因分析（PCR微阵列）
  • 全球液态切片市场（依生物标记、绩效及预测），2019-2024 年、2024-2029 年、2034 年
  • 游离去氧核糖核酸
  • 循环肿瘤去氧核糖核酸
  • 细胞外囊泡
  • 循环性肿瘤细胞
  • 其他生物标誌物
  • 全球肺癌液态切片市场（依临床应用、绩效及预测），2019-2024 年、2024-2029 年、2034 年
  • 治疗方法方案
  • 治疗监测
  • 早期癌症筛检
  • 復发监测
  • 其他用途
  • 全球肺癌液态切片市场：按最终用户、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 诊断和影像中心
  • 医院
  • 学术研究中心
  • 其他最终用户
  • 全球肺癌液态切片市场，依仪器类型细分，绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • PCR设备
  • 微阵列仪器
  • 次世代定序（NGS）仪器
  • 全球液态切片市场按消耗品套件及试剂类型细分，实际及预测，2019-2024 年、2024-2029 年、2034 年
  • 样本采集套件
  • 扩增试剂
  • 定序试剂
  • 全球液态切片市场软体和服务细分（按类型）、实际及预测，2019-2024 年、2024-2029 年、2034 年
  • 数据分析软体
  • 云端基础的服务
  • 生物资讯学工具

第七章 区域和国家分析

  • 全球肺癌液态切片市场：按地区、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 全球液态切片市场：按国家/地区、绩效及预测，2019-2024 年、2024-2029 年、2034 年

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章 澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章 德国市场

第十八章 法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章 俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章竞争格局与公司概况

  • 肺癌液态切片市场：竞争格局
  • 肺癌液态切片市场：公司简介
    • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
    • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Biocept Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Agilent Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Eurofins Scientific Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型创新企业

  • Illumina Inc.
  • Sysmex Corporation
  • Bio-Rad Laboratories Inc.
  • QIAGEN NV
  • Exact Sciences Corp
  • Natera Inc.
  • Myriad Genetics Inc.
  • NeoGenomics Laboratories Inc.
  • Guardant Health Inc.
  • MDxHealth SA
  • Exosome Diagnostics Inc.
  • Menarini Silicon Biosystems SpA
  • Inivata Ltd
  • Lucence Diagnostics Pte Ltd
  • LungLife AI Inc.

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第 35 章 高市场潜力国家、细分市场与策略

  • 2029年肺癌液态切片市场：提供新机会的国家
  • 2029年肺癌液态切片市场：细分领域带来新机会
  • 2029年肺癌液态切片市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手的策略

第36章 附录

简介目录
Product Code: r35961

Lung cancer liquid biopsy is a non-invasive method that examines blood or other bodily fluids to identify tumor-derived genetic material or cells. This technique supports early detection, genetic profiling, and monitoring of lung cancer by capturing cancer-specific biomarkers, providing an alternative to traditional surgical tissue biopsies.

Lung cancer liquid biopsy products include instruments, consumables kits and reagents, and software and services. Instruments refer to the hardware and analytical tools used to process and evaluate liquid biopsy samples. The technology applied includes multi-gene parallel analysis methods such as next-generation sequencing (NGS) and single-gene techniques like PCR and microarrays. Biomarkers analyzed include cell-free DNA, circulating tumor DNA, extracellular vesicles, circulating tumor cells, and other related indicators. These biomarkers are utilized for various purposes, including therapy selection, treatment monitoring, early cancer detection, recurrence surveillance, and other clinical applications. End-users include diagnostic and imaging centers, hospitals, academic and research institutions, and other relevant facilities.

The lung cancer liquid biopsy market research report is one of a series of new reports from The Business Research Company that provides lung cancer liquid biopsy market statistics, including the lung cancer liquid biopsy industry's global market size, regional shares, competitors with the lung cancer liquid biopsy market share, detailed lung cancer liquid biopsy market segments, market trends and opportunities, and any further data you may need to thrive in the lung cancer liquid biopsy market. This lung cancer liquid biopsy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The lung cancer liquid biopsy market size has grown rapidly in recent years. It will grow from $0.95 billion in 2024 to $1.12 billion in 2025 at a compound annual growth rate (CAGR) of 17.0%. Growth during the historic period can be attributed to the increasing prevalence of smoking- and pollution-related lung disorders, expanded use of liquid biopsy for treatment monitoring, growing investment in oncology research and development, rising demand for rapid and cost-effective diagnostic solutions, and an increasing number of clinical trials.

The lung cancer liquid biopsy market size is expected to see rapid growth in the next few years. It will grow to $2.08 billion in 2029 at a compound annual growth rate (CAGR) of 16.8%. Growth in the forecast period can be attributed to the rising incidence of lung cancer, increasing demand for non-invasive diagnostic methods, growing adoption of personalized medicine, heightened awareness of early cancer detection, and a rising geriatric population more vulnerable to cancer. Key trends expected during this period include advancements in circulating tumor DNA (ctDNA) analysis technologies, progress in exosome-based liquid biopsy techniques, innovations in microfluidics for isolating circulating tumor cells, the integration of AI and machine learning for biomarker interpretation, and technological breakthroughs enabling multiplex biomarker analysis.

The rising incidence of lung cancer is expected to drive the growth of the lung cancer liquid biopsy market in the coming years. Lung cancer is a condition marked by the uncontrolled proliferation of abnormal cells in the lungs, commonly linked to smoking and environmental exposures. The increasing number of cases is primarily attributed to continued tobacco use, which exposes the lungs to carcinogens that initiate abnormal cell growth. Liquid biopsy for lung cancer enables the detection of cancer-related genetic mutations and tumor DNA through a simple blood sample, facilitating early diagnosis, personalized treatment selection, and ongoing monitoring of disease progression or therapeutic response. For example, in 2023, the American Cancer Society reported that as of January 1, 2022, 654,620 individuals in the U.S. had a history of lung cancer, with many living with metastatic disease. Approximately 80% of these patients were aged 65 or older, and 55% had been diagnosed within the past five years, reflecting low survival rates. Consequently, the growing incidence of lung cancer is significantly contributing to the expansion of the lung cancer liquid biopsy market.

Major companies in the lung cancer liquid biopsy market are prioritizing technological advancements, such as the development of blood-based lung cancer screening tests, to improve early detection, enhance diagnostic accuracy, and provide non-invasive, real-time monitoring of tumor progression and treatment response. These blood-based screening tests analyze biomarkers in the bloodstream to detect lung cancer at an early stage, offering a less invasive alternative to traditional methods. For example, in October 2023, DELFI Diagnostics Inc., a U.S.-based biotechnology company, introduced FirstLook Lung-a blood-based liquid biopsy test aimed at early lung cancer detection. This test utilizes fragmentomics to identify early-stage lung cancer with high sensitivity and a 99.8% negative predictive value. It is designed to serve as an accessible and convenient initial screening tool for individuals at risk, with the goal of improving early detection rates, boosting screening participation, and helping prioritize imaging resources for those most likely to benefit.

In February 2024, Veracyte Inc., a U.S.-based molecular diagnostics company, acquired C2i Genomics Inc. for an undisclosed amount. Through this acquisition, Veracyte seeks to strengthen its cancer diagnostics portfolio by incorporating advanced whole-genome minimal residual disease (MRD) liquid biopsy technology to improve detection and monitoring across various cancer types. C2i Genomics Inc. is a U.S.-based company specializing in cancer detection and monitoring, including liquid biopsy tests for lung cancer.

Major players in the lung cancer liquid biopsy market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Biocept Inc., Agilent Technologies Inc., Eurofins Scientific, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Exact Sciences Corp, Natera Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Guardant Health Inc., MDxHealth SA, Exosome Diagnostics Inc., Menarini Silicon Biosystems S.p.A., Inivata Ltd, Lucence Diagnostics Pte Ltd, LungLife AI Inc., Biodesix Inc., Oncocyte Corporation.

North America was the largest region in the lung cancer liquid biopsy market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in lung cancer liquid biopsy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the lung cancer liquid biopsy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The lung cancer liquid biopsy market consists of revenues earned by entities by providing services such as mutation detection and genomic profiling, treatment monitoring, and early diagnosis and screening. The market value includes the value of related goods sold by the service provider or included within the service offering. The lung cancer liquid biopsy market also includes sales of NGS-based assays, CTC detection devices and others. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Lung Cancer Liquid Biopsy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on lung cancer liquid biopsy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for lung cancer liquid biopsy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The lung cancer liquid biopsy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product: Instruments; Sconsumables Kits And Reagents; Software And Services
  • 2) By Technology: Multi Gene-Parallel Analysis (Ngs); Single Gene Analysis (Pcr Microarrays)
  • 3) By Biomarker: Cell-Free Deoxyribonucleic Acid; Circulating Tumor Deoxyribonucleic Acid; Extracellular Vesicles; Circulating Tumor Cells; Other Biomarkers
  • 4) By Clinical Application: Therapy Selection; Treatment Monitoring; Early Cancer Screening; Recurrence Monitoring; Other Applications
  • 5) By End User: Diagnostics And Imaging Centres; Hospitals; Academics And Research Centres; Other End Users
  • Subsegments:
  • 1) By Instruments: Pcr Instruments; Microarray Instruments; Next-Generation Sequencing (Ngs) Instruments
  • 2) By Consumables Kits And Reagents: Sample Collection Kits; Amplification Reagents; Sequencing Reagents
  • 3) By Software And Services: Data Analysis Software; Cloud-Based Services; Bioinformatics Tools
  • Companies Mentioned: F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific Inc.; Biocept Inc.; Agilent Technologies Inc.; Eurofins Scientific
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Lung Cancer Liquid Biopsy Market Characteristics

3. Lung Cancer Liquid Biopsy Market Trends And Strategies

4. Lung Cancer Liquid Biopsy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Lung Cancer Liquid Biopsy Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Lung Cancer Liquid Biopsy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Lung Cancer Liquid Biopsy Market Growth Rate Analysis
  • 5.4. Global Lung Cancer Liquid Biopsy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Lung Cancer Liquid Biopsy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Lung Cancer Liquid Biopsy Total Addressable Market (TAM)

6. Lung Cancer Liquid Biopsy Market Segmentation

  • 6.1. Global Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Instruments
  • Sconsumables Kits And Reagents
  • Software And Services
  • 6.2. Global Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Multi Gene-Parallel Analysis (Ngs)
  • Single Gene Analysis (Pcr Microarrays)
  • 6.3. Global Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Cell-Free Deoxyribonucleic Acid
  • Circulating Tumor Deoxyribonucleic Acid
  • Extracellular Vesicles
  • Circulating Tumor Cells
  • Other Biomarkers
  • 6.4. Global Lung Cancer Liquid Biopsy Market, Segmentation By Clinical Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Therapy Selection
  • Treatment Monitoring
  • Early Cancer Screening
  • Recurrence Monitoring
  • Other Applications
  • 6.5. Global Lung Cancer Liquid Biopsy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Diagnostics And Imaging Centres
  • Hospitals
  • Academics And Research Centres
  • Other End Users
  • 6.6. Global Lung Cancer Liquid Biopsy Market, Sub-Segmentation Of Instruments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Pcr Instruments
  • Microarray Instruments
  • Next-Generation Sequencing (Ngs) Instruments
  • 6.7. Global Lung Cancer Liquid Biopsy Market, Sub-Segmentation Of Consumables Kits And Reagents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Sample Collection Kits
  • Amplification Reagents
  • Sequencing Reagents
  • 6.8. Global Lung Cancer Liquid Biopsy Market, Sub-Segmentation Of Software And Services, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Data Analysis Software
  • Cloud-Based Services
  • Bioinformatics Tools

7. Lung Cancer Liquid Biopsy Market Regional And Country Analysis

  • 7.1. Global Lung Cancer Liquid Biopsy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Lung Cancer Liquid Biopsy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Lung Cancer Liquid Biopsy Market

  • 8.1. Asia-Pacific Lung Cancer Liquid Biopsy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Lung Cancer Liquid Biopsy Market

  • 9.1. China Lung Cancer Liquid Biopsy Market Overview
  • 9.2. China Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Lung Cancer Liquid Biopsy Market

  • 10.1. India Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Lung Cancer Liquid Biopsy Market

  • 11.1. Japan Lung Cancer Liquid Biopsy Market Overview
  • 11.2. Japan Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Lung Cancer Liquid Biopsy Market

  • 12.1. Australia Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Lung Cancer Liquid Biopsy Market

  • 13.1. Indonesia Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Lung Cancer Liquid Biopsy Market

  • 14.1. South Korea Lung Cancer Liquid Biopsy Market Overview
  • 14.2. South Korea Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Lung Cancer Liquid Biopsy Market

  • 15.1. Western Europe Lung Cancer Liquid Biopsy Market Overview
  • 15.2. Western Europe Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Lung Cancer Liquid Biopsy Market

  • 16.1. UK Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Lung Cancer Liquid Biopsy Market

  • 17.1. Germany Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Lung Cancer Liquid Biopsy Market

  • 18.1. France Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Lung Cancer Liquid Biopsy Market

  • 19.1. Italy Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Lung Cancer Liquid Biopsy Market

  • 20.1. Spain Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Lung Cancer Liquid Biopsy Market

  • 21.1. Eastern Europe Lung Cancer Liquid Biopsy Market Overview
  • 21.2. Eastern Europe Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Lung Cancer Liquid Biopsy Market

  • 22.1. Russia Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Lung Cancer Liquid Biopsy Market

  • 23.1. North America Lung Cancer Liquid Biopsy Market Overview
  • 23.2. North America Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Lung Cancer Liquid Biopsy Market

  • 24.1. USA Lung Cancer Liquid Biopsy Market Overview
  • 24.2. USA Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Lung Cancer Liquid Biopsy Market

  • 25.1. Canada Lung Cancer Liquid Biopsy Market Overview
  • 25.2. Canada Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Lung Cancer Liquid Biopsy Market

  • 26.1. South America Lung Cancer Liquid Biopsy Market Overview
  • 26.2. South America Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Lung Cancer Liquid Biopsy Market

  • 27.1. Brazil Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Lung Cancer Liquid Biopsy Market

  • 28.1. Middle East Lung Cancer Liquid Biopsy Market Overview
  • 28.2. Middle East Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Lung Cancer Liquid Biopsy Market

  • 29.1. Africa Lung Cancer Liquid Biopsy Market Overview
  • 29.2. Africa Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Lung Cancer Liquid Biopsy Market Competitive Landscape And Company Profiles

  • 30.1. Lung Cancer Liquid Biopsy Market Competitive Landscape
  • 30.2. Lung Cancer Liquid Biopsy Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Biocept Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Agilent Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Eurofins Scientific Overview, Products and Services, Strategy and Financial Analysis

31. Lung Cancer Liquid Biopsy Market Other Major And Innovative Companies

  • 31.1. Illumina Inc.
  • 31.2. Sysmex Corporation
  • 31.3. Bio-Rad Laboratories Inc.
  • 31.4. QIAGEN N.V.
  • 31.5. Exact Sciences Corp
  • 31.6. Natera Inc.
  • 31.7. Myriad Genetics Inc.
  • 31.8. NeoGenomics Laboratories Inc.
  • 31.9. Guardant Health Inc.
  • 31.10. MDxHealth SA
  • 31.11. Exosome Diagnostics Inc.
  • 31.12. Menarini Silicon Biosystems S.p.A.
  • 31.13. Inivata Ltd
  • 31.14. Lucence Diagnostics Pte Ltd
  • 31.15. LungLife AI Inc.

32. Global Lung Cancer Liquid Biopsy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Lung Cancer Liquid Biopsy Market

34. Recent Developments In The Lung Cancer Liquid Biopsy Market

35. Lung Cancer Liquid Biopsy Market High Potential Countries, Segments and Strategies

  • 35.1 Lung Cancer Liquid Biopsy Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Lung Cancer Liquid Biopsy Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Lung Cancer Liquid Biopsy Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer